Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Current Leases (2022 - 2026)

Rani Therapeutics Holdings' Current Leases history spans 5 years, with the latest figure at $1.5 million for Q1 2026.

  • On a quarterly basis, Current Leases rose 10.19% to $1.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 million, a 10.19% increase, with the full-year FY2025 number at $1.6 million, up 8.7% from a year prior.
  • Current Leases came in at $1.5 million for Q1 2026, down from $1.6 million in the prior quarter.
  • The five-year high for Current Leases was $1.6 million in Q4 2025, with the low at $650000.0 in Q1 2022.
  • Historically, Current Leases has averaged $1.1 million across 5 years, with a median of $1.0 million in 2025.
  • Biggest five-year swings in Current Leases: fell 28.63% in 2023 and later soared 103.2% in 2024.
  • Year by year, Current Leases stood at $1.0 million in 2022, then decreased by 28.63% to $718000.0 in 2023, then surged by 103.2% to $1.5 million in 2024, then increased by 8.7% to $1.6 million in 2025, then decreased by 7.94% to $1.5 million in 2026.
  • Business Quant data shows Current Leases for RANI at $1.5 million in Q1 2026, $1.6 million in Q4 2025, and $1.0 million in Q3 2025.